These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 31735308)

  • 1. Atrial Fibrillation in Heart Failure: Focus on Antithrombotic Management.
    Obeidat M; Burgess M; Lip GYH
    Heart Fail Clin; 2020 Jan; 16(1):107-120. PubMed ID: 31735308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial Fibrillation in Heart Failure: Focus on Antithrombotic Management.
    Obeidat M; Burgess M; Lip GYH
    Cardiol Clin; 2022 May; 40(2):245-258. PubMed ID: 35465898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
    Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists.
    Sakai T; Motoki H; Fuchida A; Takeuchi T; Otagiri K; Kanai M; Kimura K; Minamisawa M; Yoshie K; Saigusa T; Ebisawa S; Okada A; Kitabayashi H; Kuwahara K
    Heart Vessels; 2022 Jul; 37(7):1232-1241. PubMed ID: 35064298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Bartels DB; Lip GY;
    J Am Coll Cardiol; 2017 Feb; 69(7):777-785. PubMed ID: 28209218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment.
    Hawkins NM; Jhund PS; Pozzi A; O'Meara E; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Petrie MC; Virani S; McMurray JJ
    Eur J Heart Fail; 2016 Sep; 18(9):1162-71. PubMed ID: 27594177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation Therapy and NOACs in Heart Failure.
    Thomas I; EncisoSilva J; Schlueter M; Greenberg B
    Handb Exp Pharmacol; 2017; 243():515-535. PubMed ID: 28233177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges.
    Ferreira JP; Girerd N; Alshalash S; Konstam MA; Zannad F
    Eur Heart J; 2016 Aug; 37(31):2455-64. PubMed ID: 27252452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
    Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
    Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant.
    Brown LAE; Boos CJ
    Int J Cardiol; 2017 Jan; 227():863-868. PubMed ID: 28029411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic treatment in atrial fibrillation.
    Lip GY; Boos CJ
    Postgrad Med J; 2008 May; 84(991):252-8. PubMed ID: 18508982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation in atrial fibrillation with heart failure.
    Zhao L; Wang WYS; Yang X
    Heart Fail Rev; 2018 Jul; 23(4):563-571. PubMed ID: 29569146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Singer DE; Albers GW; Dalen JE; Go AS; Halperin JL; Manning WJ
    Chest; 2004 Sep; 126(3 Suppl):429S-456S. PubMed ID: 15383480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
    Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation.
    Dzeshka MS; Lip GY
    Heart Fail Clin; 2016 Apr; 12(2):257-71. PubMed ID: 26968670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
    Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P
    JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.